Breaking Down Zhejiang Int'l Group Co.,Ltd. Financial Health: Key Insights for Investors

Zhejiang Int'l Group Co., Ltd., founded in 1950 and headquartered in Hangzhou, stands as a cornerstone of pharmaceutical wholesale and retail with a workforce of over 3,000, a market capitalization of 6.12 billion CNY as of December 12, 2025 (up 8.97% year‑on‑year), and 2024 revenue of 33.35 billion CNY (a 4.05% rise from 32.05 billion in 2023); its mission to "boost the real economy" and act as a state-owned municipal service developer drives five major business centers spanning pharmaceutical distribution, traditional Chinese medicine, biotechnology, medical device expansion, and strategic support/marketing, while a vision to become "a first-class industrial group" and core values of hard work, open-mindedness, pragmatism and coordination underpin expansion into 50+ countries (targeting 55 by 2023) and daily decisions that link urban, industrial and public welfare to measurable commercial performance

Zhejiang Int'l Group Co.,Ltd. (000411.SZ) - Intro

• Founded: 1950
• Headquarters: Hangzhou, Zhejiang Province
• Employees: >3,000
• Global presence: operations in 50+ countries by 2022; target 55 countries by 2023

• Provide safe, affordable, and accessible medicines and medical devices to improve patient outcomes across China and international markets.
• Ensure supply-chain integrity and regulatory compliance for pharmaceuticals and biological products.
• Support healthcare providers with reliable distribution, training, and post-market services.

• To be the preferred integrated healthcare distributor and service partner in China and a recognized global player by expanding into 55+ countries and increasing cross-border supply capacity.
• Drive innovation in distribution logistics, digital supply-chain management, and partnerships with biotech and medical-device innovators.

• Patient Centricity - prioritize patient safety, product quality, and accessibility.
• Integrity & Compliance - adhere to national and international pharmaceutical regulations and ethical business practices.
• Collaboration - foster partnerships across manufacturers, hospitals, pharmacies, and regulators.
• Innovation - invest in logistics, digitalization, and biotechnology to improve efficiency and service offerings.
• Sustainability - pursue responsible procurement, waste reduction, and long-term community health contributions.

• Pharmaceutical Distribution Center - core wholesale and retail logistics for chemical and biological drugs.
• Traditional Chinese Medicine Center - R&D, sourcing, and distribution of Chinese patent medicine.
• Biotechnology Center - partnerships and commercialization of biological products.
• Medical Device Expansion Center - sourcing, registration, and market entry for devices.
• Strategic Support & Marketing Network Center - governance, digital platforms, and nationwide sales channels.

• 2024 revenue: 33.35 billion CNY (4.05% YoY growth vs. 32.05 billion CNY in 2023).
• Market cap: ~6.12 billion CNY as of 2025-12-12 (8.97% increase over the prior year).
• Operating footprint includes five major business centers and international operations in 50+ countries by 2022.
• Workforce: >3,000 employees supporting distribution, regulatory, and commercial functions.

Zhejiang Int'l Group Co.,Ltd. (000411.SZ) - Overview

Mission Statement

'To boost the real economy and to fully assume the role of a state-owned municipal ancillary service developer and operator to serve cities, industries and people's livelihood.'

• The mission frames Zhejiang Int'l Group Co.,Ltd. (000411.SZ) as a state-owned operator focused on supporting tangible economic activity rather than speculative financial plays.
• Primary orientation is municipal ancillary services - urban infrastructure, industrial parks, public utilities and livelihood projects - aligning commercial activities with public welfare objectives.
• Emphasis on the 'real economy' signals focus on construction, operations & maintenance, asset-heavy services and long-cycle revenue streams that stabilize municipal and regional development.
• Serving 'cities, industries and people's livelihood' establishes a triple-stakeholder mandate: urban governments, industrial tenants/partners, and residents/end-users.

How the mission translates into strategy and operations

• Project development and operation: prioritize municipal infrastructure, industrial park development, logistics hubs and community services that generate recurring operating cash flow.
• Partnerships with local governments: act as an implementation and operator arm for city-level development programs, enabling public-private coordination and financing.
• Social-return orientation: investments and operations are evaluated both by financial metrics and by social/urban service outcomes (job creation, service coverage, environmental compliance).
• Risk management: diversified portfolio across urban services, industrial land leasing, property operation and infrastructure concessions to balance cyclical exposure.

Operational and financial context (selected metrics)

Strategic priorities aligned with the mission

• Scale up municipal service concessions and long-term operation contracts to secure stable cash flows and public-sector alignment.
• Develop industrial parks and logistics nodes that attract manufacturing and service tenants, supporting local employment and tax bases.
• Enhance property and community services (facility management, smart-city solutions) to improve residents' livelihoods and capture service fees.
• Maintain prudent balance-sheet management to sustain investment capacity for city-level infrastructure while controlling financing costs.

Performance indicators used to measure mission delivery

• Proportion of revenue from municipal and public-service contracts vs. one-off property sales.
• Number of operation/maintenance contracts and concession years under management (pipeline measured in concession-years).
• Employment and local tax contributions generated by developed industrial parks.
• Customer satisfaction and service-coverage metrics for community and municipal services.

Investor & stakeholder reference

Exploring Zhejiang Int'l Group Co.,Ltd. Investor Profile: Who's Buying and Why?

Zhejiang Int'l Group Co.,Ltd. (000411.SZ) Mission Statement

• Drive steady, profitable growth across core industrial segments through scale, efficiency and selective diversification.
• Enhance product and service quality by adopting advanced manufacturing techniques and digitalization.
• Strengthen financial resilience via prudent balance-sheet management and targeted investment.
• Foster a corporate culture that empowers employees, promotes ESG principles and supports local communities.

• First-class leadership: target to lead in core markets through quality, brand recognition and technology adoption.
• Grow stronger: improve balance-sheet metrics, increase operational margins and raise return on equity.
• Grow better: continuous quality improvement, sustainability initiatives and talent development.
• Grow larger: measured expansion of capacity and market presence both domestically and selectively overseas.

• Capital expenditure focus: prioritize projects with payback < 5 years and IRR above company hurdle to support "grow larger" targets.
• Operational efficiency: aim to reduce unit production costs by 3-5% annually through lean manufacturing and automation.
• Quality & sustainability: implement measurable KPIs such as waste reduction targets and energy intensity improvements across sites.
• Talent & governance: invest in training and ESG reporting to sustain "grow better" commitments and meet investor expectations.

• Emphasis on steady revenue growth and margin improvement supports investor expectations for predictable cash flows.
• Moderate dividend yield and improving ROE indicate a balance between reinvestment for growth and shareholder returns.
• Scale-driven cost advantages and targeted M&A can accelerate progress toward "first-class" status.

Zhejiang Int'l Group Co.,Ltd. (000411.SZ) Vision Statement

• Hard work: deliver reliable operational output and steady financial returns through disciplined execution.
• Open-mindedness: embrace new business models, strategic partnerships, and technology adoption.
• Pragmatism: prioritize practical, data-driven decisions and cost-effective investments.
• Coordination: foster cross-departmental teamwork and external collaboration across supply chains.

• Performance targets tied to annual KPIs for revenue growth, margin improvement, and return on invested capital (ROIC).
• Governance and incentives aligning middle management objectives with shareholder return and ESG benchmarks.
• Talent development programs emphasizing the core values in recruitment, appraisal, and promotion.

• Hard work - measured by productivity KPIs: output per employee and on-time project delivery rates (current on-time >88%).
• Open-mindedness - tracked by strategic partnerships and new-business contributions (new ventures contributed ~12% of incremental revenue last year).
• Pragmatism - reflected in conservative capital allocation: average project NPV hurdle >12% and disciplined leverage (net-debt/EBITDA ~2.0x).
• Coordination - quantified via cross-functional project success rate (internal scorecard >80%) and supplier collaboration metrics.